Sector Experts

Michael Aitkenhead

Edison Investment Research

Image: Michael Aitkenhead

Dr. Michael Aitkenhead is a qualified physician with more than 12 years' experience in the healthcare industry, including five years in clinical medicine and seven years in biopharmaceutical equity research. He was formerly a European pharmaceuticals analyst at the Royal Bank of Scotland in London, and prior to this was a European biotechnology analyst with Piper Jaffray. Aitkenhead received his medical degree from the University of Otago, New Zealand, and subsequently completed a master's degree in business administration at Judge Business School, University of Cambridge.




Recent Interviews

New Biotech Names with Excellent Prospects: Michael Aitkenhead (6/13/13) In a marketplace as diverse as biotech, picking the best and brightest can stymie even the savviest investor. Senior biotechnology analyst and physician Michael Aitkenhead of Edison Investment Research has done meticulous research on both the science and unmet needs to reveal the growth potential of biotechs with vastly different stories, disease indications and markets. In this interview with The Life Sciences Report, Aitkenhead details his thesis on three names, each with the ability to return large multiples on original investment.

Recent Quotes

"Major alliances reduce execution risk for MSB's late-stage pipeline." (11/26/13) Mesoblast Ltd. - Michael Aitkenhead, Edison Investment Research More >

"Results from CYTR's aldoxorubicin phase 2b trial support a favorable risk/benefit profile versus doxorubicin." (11/18/13) CytRx Corp. - Michael Aitkenhead, Edison Investment Research More >

"MSB's acquisition consolidates its position as the leading MSC development company." (10/21/13) Mesoblast Ltd. - Michael Aitkenhead, Edison Investment Research More >

"CYTR is well funded to advance clinical development of aldoxorubicin." (10/10/13) CytRx Corp. - Michael Aitkenhead, Edison Investment Research More >

"CYTR presented positive preclinical data for aldoxorubicin in glioblastoma multiforme." (10/2/13) CytRx Corp. - Michael Aitkenhead, Edison Investment Research More >

"We're optimistic that CYTR's aldoxorubicin will show strong advantages over alternatives." (9/3/13) CytRx Corp. - Michael Aitkenhead, Edison Investment Research More >

"CYTR will advance aldoxorubicin into phase 2b for glioblastoma multiforme." (7/23/13) CytRx Corp. - Michael Aitkenhead, Edison Investment Research More >

"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More >

more comments

"CYTR's aldoxorubicin clinical program has delivered important data points." (5/24/13) CytRx Corp. - Michael Aitkenhead, Edison Investment Research More >

"FDA agreement on CYRT's aldoxorubicin pivotal phase 3 study in second-line soft tissue sarcoma paves the way for trial initiation in Q3/13." (4/25/13) CytRx Corp. - Michael Aitkenhead, Edison Investment Research More >

"ADXN's positive dipraglurant data support a phase 2 trial in H1/13." (4/19/13) Addex Therapeutics - Michael Aitkenhead, Edison Investment Research More >

"We view the failure of Ziopharm's palifosfamide as incrementally positive for CYTR's aldoxorubicin." (3/27/13) CytRx Corp. - Michael Aitkenhead, Edison Investment Research More >

"This year could be transformative for CYTR." (3/15/13) CytRx Corp. - Michael Aitkenhead, Edison Investment Research More >

fewer comments


Due to permission requirements, not all quotes are shown.